Moreover, hs-TnT or hs-TnI added to NT-proBNP and sST2 appears to be emerging biomarkers in the prediction of adverse outcome of HF after AMI in a short-term period [115], but whether this combination is most suitable for remote prognostication in patients with known late adverse cardiac remodelling and different phenotypes of ischemia-induced HF is not fully clear. The gene discussed is NPPB; the disease is hydrops fetalis.